Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Ponderano – page 14

276 clinical trials in Ponderano, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Ponderano at a glance
276
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

276 trials in Ponderano

Open in trial search

Ovarian cancer

Not recruiting

Study on Olaparib for Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Study on the Effectiveness and Safety of Ibrutinib with Rituximab-CHOP for Untreated Patients with Diffuse Large B-cell Lymphoma at High Risk

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Fondazione Italiana Linfomi Ets

Follicular lymphoma

Not recruiting

Study Comparing Shortened vs Standard Chemotherapy with Rituximab for Initial Treatment of High Tumor Burden Follicular Lymphoma in Newly Diagnosed Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Fondazione Italiana Linfomi Ets

Study of inotuzumab ozogamicin and drug combination in adult patients with B-cell Acute Lymphoblastic Leukemia who have minimal residual disease before stem cell transplantation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Fondazione G.I.M.Em.A Franco Mandelli Ets

Study on Avelumab for Patients with High-Risk Triple Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Universita Degli Studi Di Padova

Multiple sclerosis

Not recruiting

Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Breast cancer+1

Not recruiting

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Study on Acalabrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients Without del(17p) or TP53 Mutation

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Study of Acalabrutinib and Tafasitamab for Patients with Previously Treated Marginal Zone Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Association International Extranodal Lymphoma Study Group (IELSG)

Study for Adults with Very High-Risk T-Cell Acute Lymphoblastic Leukemia Using Daratumumab and a Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aciclovir
  • Sponsor:Fondazione G.I.M.Em.A Franco Mandelli Ets

Study Comparing Venetoclax and Obinutuzumab with Drug Combination for Fit Patients with Untreated Chronic Lymphocytic Leukemia Without Specific Genetic Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:F. Hoffmann-La Roche AG

Plasma cell myeloma

Not recruiting

Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Ponderano

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on innovative treatments for various cancer types, including colorectal cancer, lymphoma, and endometrial cancer. Studies evaluate novel therapeutic combinations and personalized treatment approaches.

  • Advanced Pancreatic Cancer Treatment
  • Lymphoma Therapy Optimization
  • Targeted Colorectal Cancer Interventions

Research emphasizes improving survival rates and treatment efficacy through immunotherapy and targeted molecular approaches.

02 Neurological Disorders

Investigations into treatments for Multiple Sclerosis and Alzheimer's Disease, with particular focus on managing associated symptoms and disease progression.

  • MS Long-term Treatment Evaluation
  • Alzheimer's-related Psychosis Management
  • Innovative Therapeutic Approaches

Studies aim to enhance quality of life and develop more effective treatment strategies.

03 Infectious Diseases

Research on treating gram-negative bacterial infections in vulnerable populations, including studies of new antibiotics and treatment protocols.

  • Neonatal Infection Treatment
  • Hospital-acquired Pneumonia
  • Complex Bacterial Infections

Focus on developing safer and more effective treatments for severe infections.

04 Addiction Medicine

Studies examining treatments for alcohol dependence, with emphasis on reducing consumption and maintaining abstinence in high-risk patients.

  • Alcohol Consumption Reduction
  • Maintenance Therapy
  • Risk Level Management

Research aims to improve treatment outcomes for alcohol-dependent individuals.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.